Our finding is in line with previous studies showing that pretreatment AMH was a predictor of chemotherapy-related amenorrhea in breast cancer patients both without ovarian protection (24–26) as well as those with ovarian protection using GnRH agonists (10). The gene discussed is GNRH1; the disease is breast carcinoma.